Is Abbott Wavering Over Alere?
This article was originally published in Clinica
A non-committal response from Abbott Labs CEO Miles White about the progress of the company’s proposed acquisition of Alere, which is in the midst of a federal investigation over potentially corrupt sales practices abroad, has raised doubts about the $5.8bn transaction. White’s refusal to reaffirm the diagnostic giant’s commitment to the deal slightly eclipsed the positive financial figures it posted for the first quarter this year.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.